Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1980 3
1983 1
1993 3
1996 1
1997 3
1999 5
2001 2
2002 1
2004 6
2006 1
2007 3
2008 6
2009 2
2010 9
2011 13
2012 12
2013 19
2014 8
2015 14
2016 25
2017 37
2018 33
2019 20
2020 41
2021 30
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 27688475

254 results
Results by year
Filters applied: . Clear all
Page 1
Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers.
Park JH, Kang MJ, Ahn JH, Kim JE, Jung KH, Gong G, Lee HJ, Son BH, Ahn SH, Kim HH, Shin HJ, Moon DH, Kim SB. Park JH, et al. Cancer Chemother Pharmacol. 2016 Oct;78(4):685-95. doi: 10.1007/s00280-016-3107-6. Epub 2016 Aug 4. Cancer Chemother Pharmacol. 2016. PMID: 27491481 Clinical Trial.
A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging.
Jager A, de Vries EGE, der Houven van Oordt CWM, Neven P, Venema CM, Glaudemans AWJM, Wang Y, Bagley RG, Conlan MG, Aftimos P. Jager A, et al. Breast Cancer Res. 2020 Sep 11;22(1):97. doi: 10.1186/s13058-020-01333-3. Breast Cancer Res. 2020. PMID: 32912274 Free PMC article. Clinical Trial.
The Predictive Value of Early Changes in 18 F-Fluoroestradiol Positron Emission Tomography/Computed Tomography During Fulvestrant 500 mg Therapy in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
He M, Liu C, Shi Q, Sun Y, Zhang Y, Xu X, Yuan H, Zhang Y, Liu Y, Liu G, Di G, Yang Z, Wang Z, Shao Z. He M, et al. Oncologist. 2020 Nov;25(11):927-936. doi: 10.1634/theoncologist.2019-0561. Epub 2020 Apr 28. Oncologist. 2020. PMID: 32272493 Free PMC article.
Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
Ueda S, Tsuda H, Saeki T, Omata J, Osaki A, Shigekawa T, Ishida J, Tamura K, Abe Y, Moriya T, Yamamoto J. Ueda S, et al. Breast Cancer. 2011 Oct;18(4):299-308. doi: 10.1007/s12282-010-0212-y. Epub 2010 Jul 9. Breast Cancer. 2011. PMID: 20617404 Clinical Trial.
254 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page